Insulin detemir

Drug Profile

Insulin detemir

Alternative Names: Levemir; Levemir FlexPen; Levemir FlexTouch; LysB29-tetradecanoyl des-(B30) human insulin; NN 304

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Jun 2016 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus (In children, In adolescents) in USA, Brazil, Germany, Hungary, India, Israel, South Korea, Malaysia, Mexico, Russia, Taiwan and Turkey (NCT02131272)
  • 26 Jun 2015 The Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for insulin determir in patients aged one years and above with Type-1 diabetes mellitus
  • 25 Jun 2015 Preregistration for Type-1 diabetes mellitus (In infants) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top